V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori |
| |
| Institution: | 1. Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España;2. Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, España;3. Medicina de Familia, Centro de Salud Los Ángeles, Dirección Asistencial Centro, SERMAS, Madrid, España;4. Servicio de Aparato Digestivo, Hospital Donostia/Instituto Biodonostia, Universidad del País Vasco UPV/EHU, CIBEREHD, San Sebastián, España;5. Servicio de Aparato Digestivo, Hospital Parc Taulí, Universitat Autónoma de Barcelona, CIBEREHD, Sabadell, Barcelona, España;6. Servicio Aparato Digestivo, Hospital Universitario de Valme, CIBEREHD, Sevilla, España;7. Servicio de Aparato Digestivo, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud (SACYL), Universidad de Valladolid, Valladolid, España;8. Servicio de Urgencias, Hospital Parc Taulí Sabadell, CIBEREHD, Universitat Internacional de Catalunya, Barcelona, España;9. Servicio de Aparato Digestivo, Hospital Clínico Universitario de Zaragoza, Instituto de Investigación Sanitaria de Aragón (IIS Aragón), CIBEREHD, Zaragoza;10. Servicio de Aparato Digestivo, Hospital General de Tomelloso, CIBEREHD, Ciudad Real, España;11. Servicio de Aparato Digestivo, Hospital Universitario de Cáceres, CIBEREHD, Cáceres, España;12. Servicio de Aparato Digestivo, Agencia Sanitaria Costa del Sol, Marbella, Málaga, España;13. Servicio de Aparato Digestivo, Althaia Xarxa Assistencial Universitària de Manresa, Universitat de Vic-Universitat Central de Catalunya (UVicUCC), Manresa, Barcelona, España;1. Editor Gastroenterología, Hospital Clínic de Barcelona, Barcelona, España;2. Editor Hepatología, Hospital Clínic de Barcelona, Barcelona, España;3. Editor Enfermedad Inflamatoria Intestinal, Hospital Universitari i Politècnic La Fe, Valencia, España;4. Editor Asociado Gastroenterología, Hospital Universitario de Burgos, Burgos, España;5. Editor Asociado Hepatología, Hospital Universitario Ramón y Cajal, Madrid, España;6. Editor Asociado Enfermedad Inflamatoria Intestinal, Hospital Universitario i Politècnic La Fe, Valencia, España;1. Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;2. Division of Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Japan;3. Gastroenterology Department, Saku Central Hospital Advanced Care Center, Japan;4. Gastroenterology Department, Hospital de San Pedro, Logroño, Spain;5. Statistics, NavarraBiomed-Fundación Miguel Servet-IDISNA, Pamplona, Spain;6. Gastroenterology Department, Complejo Hospitalario de Navarra, Pamplona, Spain;7. Gastroenterology Department, Complexo Hospitalario A Coruña, Spain;8. Gastroenterology Department, Complejo Hospitalario de Vigo Hospital Xeral, Spain;9. Gastroenterology Department, Complexo Hospitalario de Ourense, Spain;10. Gastroenterology Department, HM Monteprincipe University Hospital, Madrid, Spain;11. Endoscopy Unit, Hospital del Mar, Barcelona, Spain;12. Endoscopy Department, Hospital General Universitario de Ciudad Real, Spain;13. Gastroenterology Department, Hospital Universitario de Donostia, Spain;14. Department of Gastroenterology and Hepatology, HGU Gregorio Marañon, Madrid, Spain;15. Aparato Digestivo, Hospital Universitario Puerta del Hierro, Majadahonda, Spain;p. Gastroenterology Department, Virgen de las Nieves Hospital, Granada, Spain;q. Endoscopy Unit, Hospital Lucus Augusti, Lugo, Spain;r. Digestive Diseases, Virgen Macarena University Hospital, Sevilla, Spain;s. Gastroenterology Department, Hospital Sant Joan Despi Moises Broggi, Barcelona, Spain;t. Endoscopy Unit, H. Virtual Valdecilla, Santander, Spain;u. Gastroenterology Department, Hospital Clínic de Barcelona, Spain;v. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain;w. Gastroenterology Department, Hospital General de Catalunya, Barcelona, Spain;x. Gastroenterology Department, Complejo Hospitalario La Mancha Centro, Ciudad Real, Spain;y. Gastroenterology Department, Hospital General de Ciudad Real, Spain;z. Gastroenterology Department, Complejo Asistencial Universitario de Salamanca, Spain;11. Navarrabiomed, Universidad Pública de Navarra, IdiSNa, Pamplona, Spain;1. Unidad de Cirugía Hepatobiliar, Servicio de Cirugía General y Digestiva, Hospital General Universitario de Elda, Alicante, España;2. Servicio de Anatomía Patológica, Hospital General Universitario de Elda, Alicante, España;1. Department of Infectious Diseases, Shenzhen Luohu People''s Hospital, The Third Affiliated Hospital, Shenzhen University, Shenzhen, Guangdong, China;2. Department of Infectious Diseases, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China;3. Healthcare Center, Shenzhen Luohu People''s Hospital, The Third Affiliated Hospital, Shenzhen University, Shenzhen, Guangdong, China;4. Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China;1. Servicio Aparato Digestivo, Hospital Universitario San Cecilio, Granada, España;2. Servicio Cirugía General y Digestiva, Hospital Universitario San Cecilio, Granada, España;3. Servicio Medicina Interna, Hospital Universitario San Cecilio, Granada, España;1. Servicio de Endoscopia Digestiva Centro Médico Teknon, Barcelona, Spain;2. Servicio de Gastroenterología Hospital Universitario Germans Trias i Pujol, Badalona, Spain;3. Department of Endoscopy, Fukuoka University Chikushi Hospital, Fukuoka, Japan |
| |
| Abstract: | Helicobacter pylori infection is very common in the Spanish population and represents the main cause of chronic gastritis, peptic ulcer, and gastric cancer. The last iteration of Spanish consensus guidelines on H. pylori infection was conducted in 2016. Recent changes in therapeutic schemes along with increasing supporting evidence were key for developing the V Spanish Consensus Conference (May 2021). Fourteen experts performed a systematic review of the scientific evidence and developed a series of recommendations that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. An eradication therapy, when prescribed empirically, is considered acceptable when it reliably achieves, or preferably surpass, 90% cure rates. Currently, only quadruple therapies (with or without bismuth) and generally lasting 14 days, accomplish this goal in first- and second-line therapies. A non-bismuth quadruple concomitant regimen (proton pump inhibitor, clarithromycin, amoxicillin, and metronidazole) or a quadruple bismuth-based combination (proton pump inhibitor, bismuth, tetracycline, and metronidazole), are recommended as first-line regimens. Rescue therapies after eradication failure and management of H. pylori infection in peptic ulcer disease were also reviewed. |
| |
| Keywords: | Bismuth Clarithromycin Helicobacter pylori Proton pump inhibitor Levofloxacin Metronidazole Omeprazole Tetracycline |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
